229 related articles for article (PubMed ID: 21598311)
61. Upregulation of N-acetylaspartic acid resulting nitric oxide toxicity induces aspartoacylase mutations and protein interaction to cause pathophysiology seen in Canavan disease.
Surendran S
Med Hypotheses; 2010 Dec; 75(6):533-4. PubMed ID: 20673702
[TBL] [Abstract][Full Text] [Related]
62. Dual-function AAV gene therapy reverses late-stage Canavan disease pathology in mice.
Fröhlich D; Kalotay E; von Jonquieres G; Bongers A; Lee B; Suchowerska AK; Housley GD; Klugmann M
Front Mol Neurosci; 2022; 15():1061257. PubMed ID: 36568275
[TBL] [Abstract][Full Text] [Related]
63. Aspartoacylase gene knockout results in severe vacuolation in the white matter and gray matter of the spinal cord in the mouse.
Surendran S; Campbell GA; Tyring SK; Matalon R
Neurobiol Dis; 2005 Mar; 18(2):385-9. PubMed ID: 15686967
[TBL] [Abstract][Full Text] [Related]
64. Abnormal myelinogenesis both in the white and gray matter of the attractin-deficient mv rat.
Izawa T; Yamate J; Franklin RJ; Kuwamura M
Brain Res; 2010 Feb; 1312():145-55. PubMed ID: 19931230
[TBL] [Abstract][Full Text] [Related]
65. Adenoviral gene transfer of aspartoacylase into the tremor rat, a genetic model of epilepsy, as a trial of gene therapy for inherited epileptic disorder.
Seki T; Matsubayashi H; Amano T; Kitada K; Serikawa T; Sakai N; Sasa M
Neurosci Lett; 2002 Aug; 328(3):249-52. PubMed ID: 12147318
[TBL] [Abstract][Full Text] [Related]
66. Increasing N-acetylaspartate in the Brain during Postnatal Myelination Does Not Cause the CNS Pathologies of Canavan Disease.
Appu AP; Moffett JR; Arun P; Moran S; Nambiar V; Krishnan JKS; Puthillathu N; Namboodiri AMA
Front Mol Neurosci; 2017; 10():161. PubMed ID: 28626388
[TBL] [Abstract][Full Text] [Related]
67. rAAV Gene Therapy in a Canavan's Disease Mouse Model Reveals Immune Impairments and an Extended Pathology Beyond the Central Nervous System.
Ahmed SS; Schattgen SA; Frakes AE; Sikoglu EM; Su Q; Li J; Hampton TG; Denninger AR; Kirschner DA; Kaspar B; Matalon R; Gao G
Mol Ther; 2016 Jun; 24(6):1030-1041. PubMed ID: 27039844
[TBL] [Abstract][Full Text] [Related]
68. Accumulation of N-acetyl-L-aspartate in the brain of the tremor rat, a mutant exhibiting absence-like seizure and spongiform degeneration in the central nervous system.
Kitada K; Akimitsu T; Shigematsu Y; Kondo A; Maihara T; Yokoi N; Kuramoto T; Sasa M; Serikawa T
J Neurochem; 2000 Jun; 74(6):2512-9. PubMed ID: 10820213
[TBL] [Abstract][Full Text] [Related]
69. Canavan disease: clinical features and recent advances in research.
Hoshino H; Kubota M
Pediatr Int; 2014 Aug; 56(4):477-83. PubMed ID: 24977939
[TBL] [Abstract][Full Text] [Related]
70. Metastasis-associated mts1 (S100A4) protein in the developing and adult central nervous system.
Aberg F; Kozlova EN
J Comp Neurol; 2000 Aug; 424(2):269-82. PubMed ID: 10906702
[TBL] [Abstract][Full Text] [Related]
71. Clinically Distinct Phenotypes of Canavan Disease Correlate with Residual Aspartoacylase Enzyme Activity.
Mendes MI; Smith DE; Pop A; Lennertz P; Fernandez Ojeda MR; Kanhai WA; van Dooren SJ; Anikster Y; Barić I; Boelen C; Campistol J; de Boer L; Kariminejad A; Kayserili H; Roubertie A; Verbruggen KT; Vianey-Saban C; Williams M; Salomons GS
Hum Mutat; 2017 May; 38(5):524-531. PubMed ID: 28101991
[TBL] [Abstract][Full Text] [Related]
72. Structural modeling of p.V31F variant in the aspartoacylase gene.
Krishnamoorthy N; Zayed H
Metab Brain Dis; 2016 Jun; 31(3):723-6. PubMed ID: 26797702
[TBL] [Abstract][Full Text] [Related]
73. Astroglial redistribution of aquaporin 4 during spongy degeneration in a Canavan disease mouse model.
Clarner T; Wieczorek N; Krauspe B; Jansen K; Beyer C; Kipp M
J Mol Neurosci; 2014 May; 53(1):22-30. PubMed ID: 24272958
[TBL] [Abstract][Full Text] [Related]
74. Congenital spongiform leukodystrophy in 2 female littermate German shepherd puppies.
De Miguel R; Hague DW; Johnson JL; Zilinger AM; Kukekova A; Lezmi S
J Vet Intern Med; 2024; 38(3):1730-1736. PubMed ID: 38544400
[TBL] [Abstract][Full Text] [Related]
75. Canavan disease. Analysis of the nature of the metabolic lesions responsible for development of the observed clinical symptoms.
Baslow MH; Resnik TR
J Mol Neurosci; 1997 Oct; 9(2):109-25. PubMed ID: 9407392
[TBL] [Abstract][Full Text] [Related]
76. Aspartoacylase supports oxidative energy metabolism during myelination.
Francis JS; Strande L; Markov V; Leone P
J Cereb Blood Flow Metab; 2012 Sep; 32(9):1725-36. PubMed ID: 22617649
[TBL] [Abstract][Full Text] [Related]
77. Stathmin: cellular localization of a major phosphoprotein in the adult rat and human CNS.
Peschanski M; Hirsch E; Dusart I; Doye V; Marty S; Manceau V; Sobel A
J Comp Neurol; 1993 Nov; 337(4):655-68. PubMed ID: 8288776
[TBL] [Abstract][Full Text] [Related]
78. Novel mutation in an Egyptian patient with infantile Canavan disease.
Zaki OK; El Abd HS; Mohamed SA; Zayed H
Metab Brain Dis; 2016 Jun; 31(3):573-7. PubMed ID: 26613958
[TBL] [Abstract][Full Text] [Related]
79. Mapping of phenytoin-inducible cytochrome P450 immunoreactivity in the mouse central nervous system.
Volk B; Hettmannsperger U; Papp T; Amelizad Z; Oesch F; Knoth R
Neuroscience; 1991; 42(1):215-35. PubMed ID: 1861774
[TBL] [Abstract][Full Text] [Related]
80. Mutational analysis of aspartoacylase: implications for Canavan disease.
Hershfield JR; Pattabiraman N; Madhavarao CN; Namboodiri MA
Brain Res; 2007 May; 1148():1-14. PubMed ID: 17391648
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
